Deals this Week: Pfizer, N4 Pharma, Tesaro

2 March 2018 (Last Updated March 1st, 2018 13:20)

US-based biopharmaceutical company Pfizer has filed a registration statement with the US Securities and Exchange Commission (SEC) for a public offering of securities.

US-based biopharmaceutical company Pfizer has filed a registration statement with the US Securities and Exchange Commission (SEC) for a public offering of securities.

Pfizer will offer debt securities, common stock, preferred stock, warrants, depositary shares, purchase contracts, purchase units or guarantees from time to time.

The company plans to use the proceeds for general corporate purposes, including working capital, debt repayment, dividend payment and acquisitions.

UK-based pharmaceutical company N4 Pharma has issued 716,000 shares priced at £0.085 ($0.12) a share in a private placement to raise £0.06m ($0.08m).

Tesaro has signed a clinical collaboration agreement with Roche’s subsidiary Genentech to evaluate the combination of the PD-L1 antibody atezolizumab (TECENTRIQ) and PARP-inhibitor ZEJULA (niraparib) in patients with metastatic bladder cancer.

The collaboration also includes testing Roche’s cancer immunotherapy MORPHEUS, which is currently under phase Ib/II development.

“The company plans to use the proceeds for general corporate purposes, including working capital, debt repayment, dividend payment and acquisitions.”

Both companies involved in the transaction are biotechnology companies based in the US.

US-based biopharmaceutical company CASI Pharmaceuticals has issued shares of its common stock in a public offering to raise $25m.

The company plans to use the proceeds for general corporate purposes, including research and development, commercialisation, business development and acquisitions.

CASI has appointed H.C. Wainwright & Co. as underwriter, and Arnold & Porter Kaye Scholer as legal advisor for the transaction.

Taiwanese pharmaceutical company Gongwin Biopharm Holdings has issued 4.95 million shares priced at TW$54 ($1.85) a share in a rights offering to raise TW$267.3m ($9.13m).

The company will issue 5.5 million shares to its employees and 4.95 million shares to shareholders.

Gongwin Biopharm plans to use the proceeds for working capital and to fund various research and development (R&D) projects.